Liposomal eribulin (E7389-LF) plus nivolumab: a potential treatment option for patients with advanced gastric cancer?
Ali Raza Shaikh,Daniel Lin
DOI: https://doi.org/10.21037/jgo-24-415
2024-11-02
Journal of Gastrointestinal Oncology
Abstract:Ali Raza Shaikh, Daniel Lin Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, Thomas Jefferson University, Philadelphia, PA, USA Comment on: Kawazoe A, Yamamoto N, Sugimoto N, et al . Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort. Clin Cancer Res 2024;30:1264-72. Keywords: Chemotherapy; immunotherapy; gastric cancer; nivolumab; liposomal eribulin Submitted Jun 01, 2024. Accepted for publication Sep 11, 2024. Published online Oct 21, 2024. doi: 10.21037/jgo-24-415 Gastric cancer remains the fifth most commonly diagnosed malignancy and a leading cause of cancer-related death worldwide, with an anticipated rise in disease burden to approximately 1.8 million new cases and 1.3 million deaths by the year 2040 (1). In the United States, there were estimated 26,500 new cases and 11,130 cancer-associated deaths in 2023 (2). Approximately one-third of new gastric cancer cases are unfortunately metastatic at diagnosis (2). The average five-year overall survival (OS) of all patients diagnosed with gastric cancer is less than 40%; however, the survival rate decreases to 7% if presenting with distant metastatic disease (2). Moreover, among patients with localized disease who are able to undergo curative-intent gastrectomy, more than one-third will still recur, with most recurrences occurring during the first two years after surgical resection, and the most common site of recurrence being distant (3). Therefore, improvements in therapies are strongly needed to improve survival outcomes. Over the past several years, the therapeutic landscape for advanced unresectable or metastatic gastric cancer has been significantly advanced by the incorporation of immune checkpoint inhibitor (ICI) therapy and molecular targeted agents into systemic treatment approaches. First-line strategies are presently informed by upfront molecular characterization of tumor tissue, including testing for microsatellite instability (MSI), programmed death ligand 1 (PD-L1), and human epidermal growth factor receptor 2 (HER2). For patients whose tumors are MSI-high or PD-L1 combined positive score (CPS) positive (≥5) and HER2-negative, the treatment paradigm consists of a doublet of cytotoxic chemotherapy, including a fluoropyrimidine [5-fluorouracil (5-FU) or capecitabine] plus platinum (oxaliplatin typically preferred over cisplatin due to more favorable toxicity profile) combined with an anti-programmed death 1 (PD-1) monoclonal antibody (mAb). The CheckMate 649 study demonstrated that in previously untreated patients with advanced unresectable or metastatic esophageal, gastroesophageal junction (GEJ) and gastric adenocarcinoma, the addition of nivolumab to FOLFOX (5-FU plus oxaliplatin) or CAPOX (capecitabine plus oxaliplatin) chemotherapy compared with FOLFOX or CAPOX alone improved OS [13.8 vs. 11.6 months, hazard ratio (HR) =0.80, 95% confidence interval (CI): 0.68–0.94], progression-free survival (PFS) (HR =0.77, 95% CI: 0.68–0.87), and overall response rate (ORR) (60% vs. 45%) in all randomized patients, with a larger magnitude of OS benefit (14.4 vs. 11.1 months, HR =0.71, 95% CI: 0.59–0.86) observed in patients with higher PD-L1, CPS ≥5 (4). Although the combination of fluoropyrimidine and platinum chemotherapy plus nivolumab received Food and Drug Administration (FDA) approval for all patients with advanced HER2-negative gastroesophageal adenocarcinoma in the frontline setting regardless of PD-L1 CPS score, additional analyses have called into question its benefit in patients with low PD-L1 expression (CPS <5) (5). Consequently, given the clearer benefit observed in patients with higher PD-L1 CPS score, current expert society guidelines recommend the addition of nivolumab to chemotherapy for patients with PD-L1 CPS ≥5 (6). The pivotal Trastuzumab for Gastric Cancer (ToGA) trial initially established HER2-directed therapy with trastuzumab in combination with fluoropyrimidine and platinum chemotherapy in the frontline setting for patients with HER2 overexpression, which comprise about 30% of the patient population (7). Given the potential for targeted antibody therapy combined with immunotherapy to improve immune cell filtration and T cell response, the phase III KEYNOTE 811 study, which investigated the addition of pembrolizumab to first-line trastuzumab plus fluoropyrimidine and platinum chemotherapy in patients with gastric and GEJ adenocarcinoma, demonstrated marked improvement in ORR (72.6% vs. 59.8%) with the addition of pembrolizumab, and PFS benefit primarily observed in patients with PD-L1 CPS ≥1 [10.0 vs. 8.1 months, HR =0.72, 95% CI: 0.60–0.87], with pending results on OS (8). Options for later lines of treatment for patients with gastric or GEJ adenocarcinoma with -Abstract Truncated-
oncology,gastroenterology & hepatology